The
biological diversity of the unicellular bacteriawhether
assessed by shape, food, metabolism, or ecological nichesurely
rivals (if not exceeds) that of the multicellular eukaryotes. The
relationship between bacteria whose ecological niche is the eukaryote,
and the eukaryote, is often symbiosis or stasis. Some bacteria, however,
seek advantage in this relationship. One of the most successfulto
the disadvantage of the eukaryoteis the small (less than 1
μm diameter) and nearly spherical Staphylococcus aureus bacterium. For decades, successful clinical control of its infection
has been accomplished using β-lactam antibiotics such as the
penicillins and the cephalosporins. Over these same decades S. aureus has perfected resistance mechanisms against these
antibiotics, which are then countered by new generations of β-lactam
structure. This review addresses the current breadth of biochemical
and microbiological efforts to preserve the future of the β-lactam
antibiotics through a better understanding of how S. aureus protects the enzyme targets of the β-lactams, the penicillin-binding
proteins. The penicillin-binding proteins are essential enzyme catalysts
for the biosynthesis of the cell wall, and understanding how this
cell wall is integrated into the protective cell envelope of the bacterium
may identify new antibacterials and new adjuvants that preserve the
efficacy of the β-lactams.